Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Korman, Alan"" wg kryterium: Autor


Tytuł :
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic.
Autorzy :
Etxeberria I; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Universidad de Navarra, 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, 28029 Madrid, Spain.; Navarra Institute for Health Research, 31008 Pamplona, Spain.; Department of Immunology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
Bolaños E; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Universidad de Navarra, 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, 28029 Madrid, Spain.; Navarra Institute for Health Research, 31008 Pamplona, Spain.
Teijeira A; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Universidad de Navarra, 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, 28029 Madrid, Spain.; Navarra Institute for Health Research, 31008 Pamplona, Spain.
Garasa S; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Universidad de Navarra, 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, 28029 Madrid, Spain.; Navarra Institute for Health Research, 31008 Pamplona, Spain.
Yanguas A; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Universidad de Navarra, 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, 28029 Madrid, Spain.; Navarra Institute for Health Research, 31008 Pamplona, Spain.
Azpilikueta A; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Universidad de Navarra, 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, 28029 Madrid, Spain.; Navarra Institute for Health Research, 31008 Pamplona, Spain.
Kavanaugh WM; CytomX Therapeutics, Inc., South San Francisco, CA 94080.
Vasiljeva O; CytomX Therapeutics, Inc., South San Francisco, CA 94080.
Belvin M; CytomX Therapeutics, Inc., South San Francisco, CA 94080.
Howng B; CytomX Therapeutics, Inc., South San Francisco, CA 94080.
Irving B; CytomX Therapeutics, Inc., South San Francisco, CA 94080.
Tipton K; CytomX Therapeutics, Inc., South San Francisco, CA 94080.
West J; CytomX Therapeutics, Inc., South San Francisco, CA 94080.
Mei L; CytomX Therapeutics, Inc., South San Francisco, CA 94080.
Korman AJ; Vir Biotechnology, San Francisco, CA 94158.; Immuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA 94063.
Sega E; Immuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA 94063.
Olivera I; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Universidad de Navarra, 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, 28029 Madrid, Spain.; Navarra Institute for Health Research, 31008 Pamplona, Spain.
Cirella A; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Universidad de Navarra, 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, 28029 Madrid, Spain.; Navarra Institute for Health Research, 31008 Pamplona, Spain.
Ochoa MC; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Universidad de Navarra, 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, 28029 Madrid, Spain.; Navarra Institute for Health Research, 31008 Pamplona, Spain.
Rodriguez ME; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Universidad de Navarra, 31008 Pamplona, Spain.; Department of Oncology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
Melero A; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Universidad de Navarra, 31008 Pamplona, Spain.; Department of Oncology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
Sanmamed MF; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Universidad de Navarra, 31008 Pamplona, Spain.; Department of Oncology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
Engelhardt JJ; Immuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA 94063.
Melero I; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Universidad de Navarra, 31008 Pamplona, Spain; .; Centro de Investigación Biomédica en Red de Cáncer, 28029 Madrid, Spain.; Navarra Institute for Health Research, 31008 Pamplona, Spain.; Department of Immunology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2021 Jun 29; Vol. 118 (26).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.
Autorzy :
Campbell JR; Bristol Myers Squibb, Redwood City, California.
McDonald BR; Bristol Myers Squibb, Redwood City, California.
Mesko PB; Bristol Myers Squibb, Redwood City, California.
Siemers NO; Bristol Myers Squibb, Redwood City, California.
Singh PB; Bristol Myers Squibb, Redwood City, California.
Selby M; Bristol Myers Squibb, Redwood City, California.
Sproul TW; Bristol Myers Squibb, Redwood City, California.
Korman AJ; Bristol Myers Squibb, Redwood City, California.
Vlach LM; Bristol Myers Squibb, Redwood City, California.
Houser J; Bristol Myers Squibb, Redwood City, California.
Sambanthamoorthy S; Bristol Myers Squibb, Redwood City, California.
Lu K; Bristol Myers Squibb, Redwood City, California.
Hatcher SV; Bristol Myers Squibb, Redwood City, California.
Lohre J; Bristol Myers Squibb, Redwood City, California.
Jain R; Bristol Myers Squibb, Redwood City, California. .
Lan RY; Bristol Myers Squibb, Redwood City, California. .
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2021 Jun 01; Vol. 81 (11), pp. 2983-2994. Date of Electronic Publication: 2021 Mar 23.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Author Correction: Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy.
Autorzy :
Galstyan A; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Markman JL; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Shatalova ES; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Chiechi A; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Korman AJ; Bristol-Myers Squibb, 700 Bay Road, Redwood City, CA, 94063, USA.
Patil R; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Klymyshyn D; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Tourtellotte WG; Department of Pathology and Laboratory Medicine, , Cedars-Sinai Medical Center, 8700 Beverly Blvd., ST 8719, West Hollywood, CA, 90048, USA.; Department of Biomedical Sciences, Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
Israel LL; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Braubach O; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Ljubimov VA; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Mashouf LA; Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.
Ramesh A; University of California, Los Angeles (UCLA), 621 Charles E Young Dr S, Los Angeles, CA, 90095, USA.
Grodzinski ZB; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Penichet ML; Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine at University of California, Los Angeles (UCLA), 10833 Le Conte Ave, Los Angeles, CA, 90095, USA.; Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, CA, USA.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles (UCLA), 10833 Le Conte Ave, Los Angeles, CA, 90095, USA.; The Molecular Biology Institute, University of California, Los Angeles (UCLA), 611 Charles E Young Dr E, Los Angeles, CA, 90095, USA.; AIDS Institute, University of California, Los Angeles (UCLA), 10940 Wilshire Blvd Suite 960, Los Angeles, CA, 90024, USA.; The California NanoSystems Institute, University of California, Los Angeles (UCLA), 570 Westwood Plaza Building 114, Los Angeles, CA, 90095, USA.
Black KL; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Holler E; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.; Institut für Biophysik und Physikalische Biochemie, Universität Regensburg, Regensburg, D-93040, Germany.
Sun T; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Ding H; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Ljubimov AV; Department of Biomedical Sciences, Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Ljubimova JY; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA. .; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2020 Nov 26; Vol. 11 (1), pp. 6170. Date of Electronic Publication: 2020 Nov 26.
Typ publikacji :
Published Erratum
Tytuł :
TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer.
Autorzy :
Maas RJ; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Hoogstad-van Evert JS; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands.
Van der Meer JM; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Mekers V; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Rezaeifard S; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Korman AJ; Bristol-Myers Squibb, Redwood City, CA, USA.; AK Vir Biotechnology, San Francisco, CA, USA.
de Jonge PK; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Cany J; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Woestenenk R; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Schaap NP; Department of Hematology, Radboud University Medical Center/Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Massuger LF; Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands.
Jansen JH; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Hobo W; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Dolstra H; Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Pokaż więcej
Źródło :
Oncoimmunology [Oncoimmunology] 2020 Nov 08; Vol. 9 (1), pp. 1843247. Date of Electronic Publication: 2020 Nov 08.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Killer Cells, Natural*
Ovarian Neoplasms*/drug therapy
Animals ; Antigens, CD ; Female ; Humans ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Receptors, Immunologic/genetics
Czasopismo naukowe
Tytuł :
IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Autorzy :
Chauvin JM; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania.
Ka M; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania.
Pagliano O; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania.
Menna C; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania.
Ding Q; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania.
DeBlasio R; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania.
Sanders C; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania.
Hou J; Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Li XY; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Ferrone S; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Davar D; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania.
Kirkwood JM; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania.
Johnston RJ; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California.
Korman AJ; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California.
Smyth MJ; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Zarour HM; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania. .; Department of Immunology, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania.
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Oct 15; Vol. 26 (20), pp. 5520-5533. Date of Electronic Publication: 2020 Jun 26.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target.
Autorzy :
Freeman ZT; Department of Oncology and.; Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.; Unit for Laboratory Animal Medicine, Medical School.; Rogel Cancer Center, and.
Nirschl TR; Department of Oncology and.; Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Hovelson DH; Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Johnston RJ; Bristol-Myers Squibb, Redwood City, California, USA.
Engelhardt JJ; Bristol-Myers Squibb, Redwood City, California, USA.
Selby MJ; Bristol-Myers Squibb, Redwood City, California, USA.
Kochel CM; Department of Oncology and.; Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Lan RY; Bristol-Myers Squibb, Redwood City, California, USA.
Zhai J; Department of Biostatistics, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Ghasemzadeh A; Department of Oncology and.; Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Gupta A; Department of Oncology and.; Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Skaist AM; Department of Oncology and.; Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Wheelan SJ; Department of Oncology and.; Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Jiang H; Rogel Cancer Center, and.; Department of Biostatistics, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Pearson AT; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA.
Snyder LA; Oncology Discovery, Janssen R&D, Spring House, Pennsylvania, USA.
Korman AJ; Bristol-Myers Squibb, Redwood City, California, USA.
Tomlins SA; Rogel Cancer Center, and.; Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.; Michigan Center for Translational Pathology, Department of Pathology, and.; Department of Urology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Yegnasubramanian S; Department of Oncology and.; Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.; Brady Urological Institute, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Drake CG; Department of Oncology and.; Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.; Brady Urological Institute, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.; Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, USA.
Pokaż więcej
Źródło :
The Journal of clinical investigation [J Clin Invest] 2020 Mar 02; Vol. 130 (3), pp. 1405-1416.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
4-1BB Ligand/*immunology
Lymphocytes, Tumor-Infiltrating/*immunology
Neoplasm Proteins/*immunology
Neoplasms, Experimental/*immunology
T-Lymphocytes, Regulatory/*immunology
Tumor Necrosis Factor Receptor Superfamily, Member 9/*immunology
Animals ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/pathology ; Genome-Wide Association Study ; Humans ; Lymphocyte Depletion ; Lymphocytes, Tumor-Infiltrating/pathology ; Mice, Inbred BALB C ; Neoplasms, Experimental/pathology ; Neoplasms, Experimental/therapy ; RNA-Seq ; T-Lymphocytes, Regulatory/pathology
Czasopismo naukowe
Tytuł :
Author Correction: Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy.
Autorzy :
Galstyan A; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Markman JL; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Shatalova ES; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Chiechi A; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Korman AJ; Bristol-Myers Squibb, 700 Bay Road, Redwood City, CA, 94063, USA.
Patil R; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Klymyshyn D; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Tourtellotte WG; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, 8700 Beverly Blvd., ST 8719, West Hollywood, CA, 90048, USA.; Department of Biomedical Sciences, Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
Israel LL; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Braubach O; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Ljubimov VA; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Mashouf LA; Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.
Ramesh A; University of California, Los Angeles (UCLA), 621 Charles E Young Dr S, Los Angeles, CA, 90095, USA.
Grodzinski ZB; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Penichet ML; Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine at University of California, Los Angeles (UCLA), 10833 Le Conte Ave, Los Angeles, CA, 90095, USA.; Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, CA, USA.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles (UCLA), 10833 Le Conte Ave, Los Angeles, CA, 90095, USA.; The Molecular Biology Institute, University of California, Los Angeles (UCLA), 611 Charles E Young Dr E, Los Angeles, CA, 90095, USA.; AIDS Institute, of California, Los Angeles (UCLA), 10940 Wilshire Blvd Suite 960, Los Angeles, CA, 90024, USA.; The California NanoSystems Institute, University of California, Los Angeles (UCLA), 570 Westwood Plaza Building 114, Los Angeles, CA, 90095, USA.
Black KL; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Holler E; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.; Institut für Biophysik und Physikalische Biochemie, Universität Regensburg, Regensburg, D-93040, Germany.
Sun T; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Ding H; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Ljubimov AV; Department of Biomedical Sciences, Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Ljubimova JY; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA. .; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2020 Jan 30; Vol. 11 (1), pp. 701. Date of Electronic Publication: 2020 Jan 30.
Typ publikacji :
Published Erratum
Tytuł :
Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV Cancers.
Autorzy :
Galliverti G; Swiss Institute for Experimental Cancer Research, School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.; Institute of Bioengineering, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.
Wullschleger S; Swiss Institute for Experimental Cancer Research, School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.; Swiss Cancer Center Leman (SCCL), Lausanne, Switzerland.
Tichet M; Swiss Institute for Experimental Cancer Research, School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.
Murugan D; Department of Cell, Developmental & Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Zangger N; Swiss Institute for Experimental Cancer Research, School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.; Bioinformatics Core Facility, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.; Translational Bioinformatics and Statistics, Swiss Cancer Center Lausanne, Lausanne, Switzerland.; Department of Oncology, University of Lausanne, Lausanne, Switzerland.
Horton W; Computational Biology Program, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Korman AJ; Bristol-Myers Squibb Company, Immuno-oncology Research, Redwood City, California.
Coussens LM; Department of Cell, Developmental & Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
Swartz MA; Institute for Molecular Engineering, University of Chicago, Chicago, Illinois.; The Ben May Department for Cancer Research, University of Chicago, Chicago, Illinois.
Hanahan D; Swiss Institute for Experimental Cancer Research, School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland. .; Swiss Cancer Center Leman (SCCL), Lausanne, Switzerland.
Pokaż więcej
Źródło :
Cancer immunology research [Cancer Immunol Res] 2020 Jan; Vol. 8 (1), pp. 131-145. Date of Electronic Publication: 2019 Nov 26.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents, Immunological/*pharmacology
CD8-Positive T-Lymphocytes/*immunology
Myeloid Cells/*immunology
Papillomaviridae/*immunology
Papillomavirus Infections/*immunology
Papillomavirus Vaccines/*immunology
Uterine Cervical Neoplasms/*immunology
Animals ; CTLA-4 Antigen/antagonists & inhibitors ; Disease Models, Animal ; Drug Synergism ; Female ; Humans ; Immunosuppression ; Immunotherapy/methods ; Mice ; Myeloid Cells/drug effects ; Nanoparticles/administration & dosage ; Papillomavirus E7 Proteins/immunology ; Papillomavirus E7 Proteins/metabolism ; Papillomavirus Infections/drug therapy ; Papillomavirus Infections/virology ; Papillomavirus Vaccines/administration & dosage ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Tumor Microenvironment ; Uterine Cervical Neoplasms/drug therapy ; Uterine Cervical Neoplasms/pathology ; Uterine Cervical Neoplasms/virology
Czasopismo naukowe
Tytuł :
Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance.
Autorzy :
Nambiar DK; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
Aguilera T; Department of Radiation Oncology, University of Texas Southwestern, Dallas, Texas, USA.
Cao H; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
Kwok S; Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.
Kong C; Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.
Bloomstein J; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
Wang Z; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, USA.
Rangan VS; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, USA.
Jiang D; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
von Eyben R; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
Liang R; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
Agarwal S; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
Colevas AD; Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
Korman A; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, USA.
Allen CT; Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders (NIDCD), Bethesda, Maryland, USA.
Uppaluri R; Department of Surgery - Otolaryngology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Koong AC; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Giaccia A; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
Le QT; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
Pokaż więcej
Źródło :
The Journal of clinical investigation [J Clin Invest] 2019 Dec 02; Vol. 129 (12), pp. 5553-5567.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
B7-H1 Antigen/*antagonists & inhibitors
Endothelium/*physiology
Galectin 1/*physiology
Head and Neck Neoplasms/*drug therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
T-Lymphocytes/*immunology
Adult ; Aged ; Aged, 80 and over ; Animals ; B7-H1 Antigen/physiology ; Female ; Galectin 1/antagonists & inhibitors ; Galectins/physiology ; Head and Neck Neoplasms/immunology ; Humans ; Immune Tolerance ; Immunotherapy ; Male ; Mice ; Mice, Inbred C57BL ; Middle Aged ; STAT1 Transcription Factor/physiology
Czasopismo naukowe
Tytuł :
An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors.
Autorzy :
Wang R; Sanofi, Oncology Clinical Translational Medicine, Cambridge, Massachusetts.
Gao C; Bristol-Myers Squibb, Discovery Oncology, Redwood City, California.
Raymond M; Bristol-Myers Squibb, Discovery Oncology, Redwood City, California.
Dito G; Bristol-Myers Squibb, Princeton, New Jersey.
Kabbabe D; Bristol-Myers Squibb, Princeton, New Jersey.
Shao X; Bristol-Myers Squibb, Princeton, New Jersey.
Hilt E; Bristol-Myers Squibb, Princeton, New Jersey.
Sun Y; Bristol-Myers Squibb, Princeton, New Jersey.
Pak I; Bristol-Myers Squibb, Princeton, New Jersey.
Gutierrez M; Divisions of Thoracic Oncology and Gastrointestinal Oncology, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey.
Melero I; Immunology and Immunotherapy Service, Center for Applied Medical Research, Clinica Universidad de Navarra, Pamplona, Spain.
Spreafico A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.; Department of Medicine, University of Toronto, Toronto, Canada.; Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Carvajal RD; Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, New York.
Ong M; Department of Medicine, Division of Medical Oncology, University of Ottawa, Ottawa, Ontario, Canada.
Olszanski AJ; Department of Hematology/Oncology, Fox Chase Cancer Center, Temple University, Philadelphia, Pennsylvania.
Milburn C; Bristol-Myers Squibb, Princeton, New Jersey.
Thudium K; Bristol-Myers Squibb, Princeton, New Jersey.
Yang Z; Bristol-Myers Squibb, Princeton, New Jersey.
Feng Y; Bristol-Myers Squibb, Princeton, New Jersey.
Fracasso PM; Adaptimmune LLC, Philadelphia, Pennsylvania.
Korman AJ; Bristol-Myers Squibb, Discovery Oncology, Redwood City, California.
Aanur P; Bristol-Myers Squibb, Princeton, New Jersey.
Huang SA; AbbVie, Translational Oncology, Redwood City, California.
Quigley M; Bristol-Myers Squibb, Discovery Oncology, Redwood City, California. .
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Nov 15; Vol. 25 (22), pp. 6709-6720. Date of Electronic Publication: 2019 Oct 01.
Typ publikacji :
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Molecular Targeted Therapy*/adverse effects
Molecular Targeted Therapy*/methods
Antineoplastic Agents, Immunological/*therapeutic use
Neoplasms/*drug therapy
Neoplasms/*pathology
Receptors, OX40/*agonists
Animals ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; CTLA-4 Antigen/antagonists & inhibitors ; Cytokines/metabolism ; Disease Models, Animal ; Humans ; Immunophenotyping ; Mice ; Mice, Transgenic ; Neoplasm Metastasis ; Neoplasm Staging ; Neoplasms/metabolism ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy.
Autorzy :
Galstyan A; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Markman JL; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Shatalova ES; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Chiechi A; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Korman AJ; Bristol-Myers Squibb, 700 Bay Road, Redwood City, CA, 94063, USA.
Patil R; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Klymyshyn D; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Tourtellotte WG; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, 8700 Beverly Blvd., ST 8719, West Hollywood, CA, 90048, USA.; Department of Biomedical Sciences, Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.
Israel LL; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Braubach O; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Ljubimov VA; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Mashouf LA; Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA.
Ramesh A; University of California, Los Angeles (UCLA), 621 Charles E Young Dr S, Los Angeles, CA, 90095, USA.
Grodzinski ZB; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Penichet ML; Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine at University of California, Los Angeles (UCLA), 10833 Le Conte Ave, Los Angeles, CA, 90095, USA.; Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, CA, USA.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles (UCLA), 10833 Le Conte Ave, Los Angeles, CA, 90095, USA.; The Molecular Biology Institute, University of California, Los Angeles (UCLA), 611 Charles E Young Dr E, Los Angeles, CA, 90095, USA.; AIDS Institute, University of California, Los Angeles (UCLA), 10940 Wilshire Blvd Suite 960, Los Angeles, CA, 90024, USA.; The California NanoSystems Institute, University of California, Los Angeles (UCLA), 570 Westwood Plaza Building 114, Los Angeles, CA, 90095, USA.
Black KL; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Holler E; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.; Institut für Biophysik und Physikalische Biochemie, Universität Regensburg, Regensburg, D-93040, Germany.
Sun T; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Ding H; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Ljubimov AV; Department of Biomedical Sciences, Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA.
Ljubimova JY; Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, AHSP, Los Angeles, CA, 90048, USA. .; Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2019 Aug 28; Vol. 10 (1), pp. 3850. Date of Electronic Publication: 2019 Aug 28.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antineoplastic Agents, Immunological/*administration & dosage
Brain Neoplasms/*drug therapy
Glioma/*drug therapy
Immunoconjugates/*administration & dosage
Nanoconjugates/*chemistry
Animals ; Antineoplastic Agents, Immunological/pharmacokinetics ; Biopolymers/chemistry ; Blood-Brain Barrier/metabolism ; Brain Neoplasms/immunology ; Brain Neoplasms/pathology ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/immunology ; Cell Line, Tumor/transplantation ; Disease Models, Animal ; Female ; Glioma/immunology ; Glioma/pathology ; Humans ; Immunoconjugates/chemistry ; Immunoconjugates/pharmacokinetics ; Malates/chemistry ; Mice ; Permeability ; Physarum polycephalum/chemistry ; Polymers/chemistry ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
CD96 Is an Immune Checkpoint That Regulates CD8 T-cell Antitumor Function.
Autorzy :
Mittal D; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Lepletier A; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Madore J; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Aguilera AR; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Stannard K; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Blake SJ; Cancer Immunoregulation and Immunotherapy, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Whitehall VLJ; The Conjoint Gastroenterology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.; Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia.
Liu C; The Conjoint Gastroenterology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.; Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia.; Envoi Specialist Pathologists, Kelvin Grove, Queensland, Australia.
Bettington ML; Envoi Specialist Pathologists, Kelvin Grove, Queensland, Australia.
Takeda K; Division of Cell Biology, Biomedical Research Center, Juntendo University, Bunkyo-ku, Tokyo, Japan.; Department of Biofunctional Microbiota, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan.
Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.; The University of Sydney, New South Wales, Australia.
Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; The University of Sydney, New South Wales, Australia.
Lan R; Bristol-Myers Squibb, New York, New York.
Siemers N; Bristol-Myers Squibb, New York, New York.
Korman A; Bristol-Myers Squibb, New York, New York.
Teng MWL; Cancer Immunoregulation and Immunotherapy, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Johnston RJ; Bristol-Myers Squibb, New York, New York.
Dougall WC; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Smyth MJ; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. .
Pokaż więcej
Źródło :
Cancer immunology research [Cancer Immunol Res] 2019 Apr; Vol. 7 (4), pp. 559-571. Date of Electronic Publication: 2019 Mar 20.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antigens, CD/*immunology
CD8-Positive T-Lymphocytes/*immunology
Lymphocytes, Tumor-Infiltrating/*immunology
Neoplasms/*immunology
Adoptive Transfer ; Animals ; Antigens, CD/genetics ; Cell Line, Tumor ; Humans ; Male ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Mice, Transgenic ; Neoplasms/therapy
Czasopismo naukowe
Tytuł :
New epitopes in ovalbumin provide insights for cancer neoepitopes.
Autorzy :
Karandikar SH; Department of Immunology, University of Connecticut School of Medicine, Farmington, Connecticut, USA.
Sidney J; Division of Vaccine Discovery, La Jolla Institute of Allergy and Immunology, La Jolla, California, USA.
Sette A; Division of Vaccine Discovery, La Jolla Institute of Allergy and Immunology, La Jolla, California, USA.
Selby MJ; Bristol-Myers Squibb, Redwood City, California, USA.
Korman AJ; Bristol-Myers Squibb, Redwood City, California, USA.
Srivastava PK; Department of Immunology, University of Connecticut School of Medicine, Farmington, Connecticut, USA.; Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine, Farmington, Connecticut, USA.
Pokaż więcej
Źródło :
JCI insight [JCI Insight] 2019 Mar 14; Vol. 5. Date of Electronic Publication: 2019 Mar 14.
Typ publikacji :
Journal Article
MeSH Terms :
Antigens, Neoplasm/*immunology
CD8-Positive T-Lymphocytes/*immunology
Epitopes, T-Lymphocyte/*immunology
Neoplasms/*immunology
Ovalbumin/*immunology
Animals ; Antigens, Neoplasm/genetics ; Cell Line, Tumor/transplantation ; Computational Biology ; Disease Models, Animal ; Epitope Mapping/methods ; Epitopes, T-Lymphocyte/genetics ; Female ; Histocompatibility Antigens Class I/genetics ; Histocompatibility Antigens Class I/immunology ; Humans ; Mice ; Mice, Transgenic ; Neoplasms/pathology ; Ovalbumin/genetics
Czasopismo naukowe
Tytuł :
Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy.
Autorzy :
Tu MM; Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Lee FYF; Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Jones RT; Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Kimball AK; Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Saravia E; Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Graziano RF; Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Coleman B; Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.
Menard K; Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Yan J; Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Michaud E; Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Chang H; Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Abdel-Hafiz HA; Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Rozhok AI; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, CO, USA.
Duex JE; Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Agarwal N; Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Chauca-Diaz A; Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Johnson LK; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Ng TL; Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.
Cambier JC; Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, USA.
Clambey ET; Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Costello JC; Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Korman AJ; Bristol-Myers Squibb, Redwood City, CA, USA.
Theodorescu D; Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA.
Pokaż więcej
Źródło :
Science advances [Sci Adv] 2019 Feb 20; Vol. 5 (2), pp. eaav2437. Date of Electronic Publication: 2019 Feb 20 (Print Publication: 2019).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Delivery Systems*
Immunity, Cellular*
Immunotherapy*
CD8-Positive T-Lymphocytes/*immunology
Dasatinib/*pharmacology
Discoidin Domain Receptor 2/*antagonists & inhibitors
Neoplasms, Experimental/*therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Animals ; CD8-Positive T-Lymphocytes/pathology ; Cell Line, Tumor ; Discoidin Domain Receptor 2/immunology ; Female ; Mice ; Neoplasms, Experimental/immunology ; Neoplasms, Experimental/pathology ; Programmed Cell Death 1 Receptor/immunology
Czasopismo naukowe
Tytuł :
Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma.
Autorzy :
Harris-Bookman S; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Mathios D; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Martin AM; Department of Oncology and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Xia Y; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Kim E; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Xu H; Department of Dermatology, The Johns Hopkins University School of Medicine, Baltimore, MD.
Belcaid Z; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Polanczyk M; Department of Oncology and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Barberi T; Department of Oncology and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Theodros D; Department of Oncology and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Kim J; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Taube JM; Department of Dermatology, The Johns Hopkins University School of Medicine, Baltimore, MD.
Burger PC; Department of Neuropathology, Johns Hopkins University School of Medicine, Baltimore, MD.
Selby M; Bristol-Myers Squibb Company, New York, NY.
Taitt C; Bristol-Myers Squibb Company, New York, NY.
Korman A; Bristol-Myers Squibb Company, New York, NY.
Ye X; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Drake CG; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY.
Brem H; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Pardoll DM; Department of Oncology and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.; Division Pediatric Oncology, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD.
Lim M; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Pokaż więcej
Źródło :
International journal of cancer [Int J Cancer] 2018 Dec 15; Vol. 143 (12), pp. 3201-3208. Date of Electronic Publication: 2018 Sep 24.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Blocking/*therapeutic use
Antibodies, Monoclonal/*therapeutic use
Antigens, CD/*immunology
Antineoplastic Agents, Immunological/*therapeutic use
Brain Neoplasms/*therapy
Glioblastoma/*therapy
Programmed Cell Death 1 Receptor/*immunology
Aged ; Animals ; Antibodies, Blocking/immunology ; Antibodies, Monoclonal/immunology ; Antigens, CD/genetics ; Brain Neoplasms/immunology ; Cell Line, Tumor ; Female ; Flow Cytometry ; Glioblastoma/immunology ; Humans ; Immunohistochemistry ; Immunologic Memory ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Middle Aged ; Survival Analysis ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.
Autorzy :
Marciscano AE; Department of Radiation Oncology & Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Ghasemzadeh A; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Nirschl TR; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Theodros D; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Kochel CM; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Francica BJ; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Muroyama Y; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Anders RA; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Department of Pathology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Sharabi AB; Department of Radiation Medicine and Applied Sciences, University of California, San Diego, Moores Cancer Center, San Diego, California.
Velarde E; Department of Radiation Oncology & Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Mao W; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Chaudhary KR; Department of Radiation Oncology, Columbia University Medical Center, New York, New York.
Chaimowitz MG; Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.
Wong J; Department of Radiation Oncology & Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Selby MJ; Bristol-Myers Squibb Company, Redwood City, California.
Thudium KB; Bristol-Myers Squibb Company, Redwood City, California.
Korman AJ; Bristol-Myers Squibb Company, Redwood City, California.
Ulmert D; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Thorek DLJ; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.
DeWeese TL; Department of Radiation Oncology & Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Drake CG; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. .; Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2018 Oct 15; Vol. 24 (20), pp. 5058-5071. Date of Electronic Publication: 2018 Jun 13.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy*/methods
Radiosurgery*/methods
Lymph Nodes/*pathology
Lymph Nodes/*radiation effects
Neoplasms/*pathology
Neoplasms/*therapy
Adoptive Transfer ; Animals ; Cell Line, Tumor ; Combined Modality Therapy ; Cytokines/metabolism ; Disease Models, Animal ; Humans ; Lymph Nodes/immunology ; Lymph Nodes/metabolism ; Lymphocytes, Tumor-Infiltrating/immunology ; Lymphocytes, Tumor-Infiltrating/metabolism ; Lymphocytes, Tumor-Infiltrating/pathology ; Melanoma, Experimental ; Mice ; Neoplasms/immunology ; Neoplasms/metabolism ; Prognosis ; T-Cell Antigen Receptor Specificity ; T-Lymphocyte Subsets/immunology ; T-Lymphocyte Subsets/metabolism ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
CD226 opposes TIGIT to disrupt Tregs in melanoma.
Autorzy :
Fourcade J; Department of Medicine and Division of Hematology/Oncology and.
Sun Z; Department of Medicine and Division of Hematology/Oncology and.
Chauvin JM; Department of Medicine and Division of Hematology/Oncology and.
Ka M; Department of Medicine and Division of Hematology/Oncology and.
Davar D; Department of Medicine and Division of Hematology/Oncology and.
Pagliano O; Department of Medicine and Division of Hematology/Oncology and.
Wang H; Department of Biostatistics, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, USA.
Saada S; Department of Medicine and Division of Hematology/Oncology and.
Menna C; Department of Medicine and Division of Hematology/Oncology and.
Amin R; Department of Medicine and Division of Hematology/Oncology and.
Sander C; Department of Medicine and Division of Hematology/Oncology and.
Kirkwood JM; Department of Medicine and Division of Hematology/Oncology and.
Korman AJ; Bristol-Myers Squibb, Biologics Discovery California, Redwood City, California, USA.
Zarour HM; Department of Medicine and Division of Hematology/Oncology and.; Department of Immunology, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania, USA.
Pokaż więcej
Źródło :
JCI insight [JCI Insight] 2018 Jul 26; Vol. 3 (14). Date of Electronic Publication: 2018 Jul 26 (Print Publication: 2018).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Antigens, Differentiation, T-Lymphocyte/*metabolism
Melanoma/*metabolism
Receptors, Immunologic/*metabolism
CD4-Positive T-Lymphocytes/metabolism ; CD8-Positive T-Lymphocytes ; Cytokines ; Humans ; Immunophenotyping ; Immunotherapy ; Lymphocyte Activation ; Melanoma/therapy ; T-Lymphocytes, Regulatory/immunology ; Tumor Suppressor Proteins/metabolism
Czasopismo naukowe
Tytuł :
Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites.
Autorzy :
Morris ZS; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. .
Guy EI; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Werner LR; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Carlson PM; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Heinze CM; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Kler JS; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Busche SM; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Jaquish AA; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Sriramaneni RN; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Carmichael LL; Department of Biostatistics and Bioinformatics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Loibner H; Apeiron Biologics, Vienna, Austria.
Gillies SD; Provenance Biopharmaceuticals, Carlisle, Massachusetts.
Korman AJ; Bristol-Myers Squibb, Redwood City, California.
Erbe AK; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Hank JA; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Rakhmilevich AL; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Harari PM; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Sondel PM; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.; Departments of Pediatrics and Genetics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Pokaż więcej
Źródło :
Cancer immunology research [Cancer Immunol Res] 2018 Jul; Vol. 6 (7), pp. 825-834. Date of Electronic Publication: 2018 May 10.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Cancer Vaccines/*immunology
Neoplasms/*immunology
Animals ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/immunology ; CTLA-4 Antigen/metabolism ; Cancer Vaccines/therapeutic use ; Cell Line, Tumor ; Combined Modality Therapy ; Disease Models, Animal ; Humans ; Immune Tolerance ; Melanoma/immunology ; Melanoma/metabolism ; Melanoma/pathology ; Melanoma/therapy ; Mice ; Neoplasms/metabolism ; Neoplasms/pathology ; Neoplasms/therapy ; T-Lymphocytes, Regulatory/immunology ; T-Lymphocytes, Regulatory/metabolism ; Vaccination ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients.
Autorzy :
Colston E; Innovative Medicines Development, Bristol-Myers Squibb, Princeton, New Jersey, United States of America.
Grasela D; Innovative Medicines Development, Bristol-Myers Squibb, Princeton, New Jersey, United States of America.
Gardiner D; Infectious Diseases Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America.
Bucy RP; Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Vakkalagadda B; Clinical Pharmacology and Pharmacometrics, Bristol-Myers Squibb, Hopewell, New Jersey, United States of America.
Korman AJ; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, United States of America.
Lowy I; Translational Science and Clinical Oncology, Regeneron Pharmaceuticals, Tarrytown, New York, United States of America.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2018 Jun 07; Vol. 13 (6), pp. e0198158. Date of Electronic Publication: 2018 Jun 07 (Print Publication: 2018).
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
CTLA-4 Antigen/*immunology
HIV Infections/*drug therapy
HIV-1/*immunology
Ipilimumab/*administration & dosage
Viremia/*drug therapy
Adult ; CD4 Lymphocyte Count ; CTLA-4 Antigen/antagonists & inhibitors ; Dose-Response Relationship, Drug ; Female ; HIV Infections/immunology ; HIV Infections/metabolism ; HIV Infections/virology ; Humans ; Ipilimumab/adverse effects ; Ipilimumab/pharmacokinetics ; Male ; Maximum Tolerated Dose ; Middle Aged ; RNA, Viral/blood ; Viremia/immunology ; Viremia/metabolism
Czasopismo naukowe
Tytuł :
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM.
Autorzy :
Hung AL; Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Maxwell R; Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Theodros D; Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.; Department of Oncology, Johns Hopkins Hospital, Baltimore, MD, USA.
Belcaid Z; Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Mathios D; Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Luksik AS; Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Kim E; Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Wu A; Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Xia Y; Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Garzon-Muvdi T; Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Jackson C; Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Ye X; Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Tyler B; Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Selby M; Bristol-Myers Squibb, New York, NY, USA.
Korman A; Bristol-Myers Squibb, New York, NY, USA.
Barnhart B; Bristol-Myers Squibb, New York, NY, USA.
Park SM; Wide River Institute of Immunology, Seoul National University College of Medicine, Hongcheon, Korea.
Youn JI; Wide River Institute of Immunology, Seoul National University College of Medicine, Hongcheon, Korea.; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.
Chowdhury T; Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea.
Park CK; Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea.
Brem H; Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Pardoll DM; Department of Oncology, Johns Hopkins Hospital, Baltimore, MD, USA.
Lim M; Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, MD, USA.
Pokaż więcej
Źródło :
Oncoimmunology [Oncoimmunology] 2018 May 24; Vol. 7 (8), pp. e1466769. Date of Electronic Publication: 2018 May 24 (Print Publication: 2018).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies